Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01682681
Recruitment Status : Completed
First Posted : September 11, 2012
Results First Posted : August 16, 2013
Last Update Posted : September 6, 2013
Sponsor:
Information provided by (Responsible Party):
Janssen Korea, Ltd., Korea

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the long-term retention rate of topiramate in participants with epilepsy (seizure disorder).

Condition or disease Intervention/treatment
Epilepsy Drug: Topiramate

Detailed Description:
This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), single-arm, prospective (study following participants forward in time), observational (a clinical study in which participants identified as belonging to study groups are assessed for biomedical or health outcomes) and multi-center (when more than one hospital or medical school team work on a medical research study) study of topiramte in participants with epilesy. The study population will be all the epilepsy participants visiting outpatient study center over a period of two months. Topiramate will be administered as per Investigator's discretion for 52 weeks. Participants will visit the trial site for evaluation of endpoint at Baseline, Week 12, Week 26, and Week 52. Efficacy will primarily be evaluated by percentage of participants which will be retained to topiramate treatment uptil Week 52. Participants' safety will be monitored throughout the study.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 1234 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Prospective, Observational, Multi-center Study to Assess Long-term Retention Rate of Topiramate in Patients With Epilepsy
Study Start Date : July 2007
Actual Primary Completion Date : May 2009
Actual Study Completion Date : May 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy
Drug Information available for: Topiramate

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Topiramate Drug: Topiramate
This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of Participants Retained to Topiramate Treatment [ Time Frame: Week 52 ]
    Participants with long term retention of topiramate until 52 weeks were reported


Secondary Outcome Measures :
  1. Number of Participants Who Received Concomitant Antiepileptic Drugs (AEDs) [ Time Frame: Baseline up to Week 52 ]
    Number of participants who received concomitant AEDs along with the topiramate were reported.

  2. Number of Participants Who Received Topiramate as First Mono-therapy, Second Mono-therapy or Add-on Therapy [ Time Frame: Baseline up to Week 52 ]
    Number of participants who received topiramate as first mono-therapy (initial treatment of epilepsy with a single drug), second mono-therapy (second line treatment with a single drug) or add-on therapy (as a supplement therapy to another drug) were reported.

  3. Percentage of Participants Without Seizure [ Time Frame: Baseline up to Week 52 ]
    Participants without seizure was calculated as percentage of participants who were found to be free of seizures and were observed up to Week 52.

  4. Percentage of Participants With Reduction in Seizure Frequency by 50 Percent or More [ Time Frame: Week 52 ]
    Percentage of participants for whom seizure frequency was reduced by greater than or equal to 50 percent after topiramate treatment were reported.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population will include participants with epilepsy who visit an out-patient clinic for two months and have not received topiramate treatment for at least three months prior to Screening.
Criteria

Inclusion Criteria:

  • Participants with all type of epilepsy
  • Participants with more than 2 episodes of seizure during last 1 year
  • Participants who can comply with the visit schedule and are willing and able to complete evaluation procedures specified in the protocol during the treatment period
  • Female participants with child bearing potential and who use proper contraceptive methods during the study period

Exclusion Criteria:

  • Participants who have known hypersensitivity reaction or allergy to the study drug
  • Participants who have taken topiramate within the three months of study start
  • Participants who are determined not to be suitable for the clinical study participation by an Investigator's discretion
  • Pregnant and nursing female participants
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01682681


Sponsors and Collaborators
Janssen Korea, Ltd., Korea
Investigators
Layout table for investigator information
Study Director: Janssen Korea, Ltd., Korea Clinical Trial Janssen Korea, Ltd., Korea
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Janssen Korea, Ltd., Korea
ClinicalTrials.gov Identifier: NCT01682681    
Other Study ID Numbers: CR015865
TOPMATEPY4053
First Posted: September 11, 2012    Key Record Dates
Results First Posted: August 16, 2013
Last Update Posted: September 6, 2013
Last Verified: August 2013
Keywords provided by Janssen Korea, Ltd., Korea:
Epilepsy
Topiramate
Topmax
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Topiramate
Anticonvulsants
Hypoglycemic Agents
Physiological Effects of Drugs